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ABSTRACT
CONTEXT AND OBJECTIVE: Non-myeloablative hematopoietic stem cell transplantation (NMA-HSCT) is performed in onco-hematological patients who 
cannot tolerate ablative conditioning because of older age or comorbidities. This approach does not completely eliminate host cells and initially results in 
mixed chimerism. Long-term persistence of mixed chimerism results in graft rejection and relapse. Involvement of graft-versus-host disease is concomitant 
with complete chimerism and graft-versus-tumor effect. The aim of this study was to evaluate the prevalence of chimerism in onco-hematological patients 
who underwent NMA-HSCT. 
DESIGN AND SETTING: Observational clinical study on chimerism status after human leukocyte antigen-identical NMA-HSCT at the Discipline of Hematology 
and Hemotherapy of Universidade Federal de São Paulo. 
METHODS: We sequentially analyzed the amplification of APO-B, D1S80, DxS52, FVW, 33.6, YNZ-2 and H-ras primers using variable number of tandem 
repeats (VNTR) on 17 pairs and fluorescent in situ hybridization (FISH) with the XY probe and SRY primer on 13 sex-unmatched pairs. 
RESULTS: The informativeness of the primers using VNTR was 60% for APO-B, 75% D1S80, 36% DxS52, 14% FVW, 40% YNZ-22 and 16% H-ras. The SRY 
primer was informative in female receptors with male donors. The XY-FISH method was informative in 100% of the sex-unmatched pairs. 
CONCLUSION: These methods were sensitive and informative. In VNTR, the association of APO-B with D1S80 showed 88% informativeness. The quantitative 
FISH method was more sensitive, but had the disadvantage of only being used for sex-unmatched pairs. 
RESUMO
CONTEXTO E OBJETIVO: O transplante de células hematopoiéticas não-mieloablativo é realizado em pacientes com doenças onco-hematológicas que não 
suportam condicionamentos ablativos devido à elevada idade ou ao acometimento por comorbidades. Esta abordagem não elimina completamente as 
células do hospedeiro, resultando, inicialmente, em quimerismo misto. A persistência do quimerismo misto na evolução de longo prazo resulta na rejeição 
ao enxerto e recaída. O acometimento pela doença do enxerto contra hospedeiro é concomitante ao quimerismo completo e ao efeito enxerto versus 
tumor. O objetivo deste estudo foi avaliar a prevalência do quimerismo em doenças onco-hematológicas tratadas com o transplante não-mieloablativo 
de células hematopoiéticas. 
TIPO DE ESTUDO E LOCAL: Estudo clínico observacional do estado de quimerismo após transplante antígenos leucocitários humanos-idêntico não-
mieloabaltivo realizado na Disciplina de Hematologia e Hemoterapia da Universidade Federal de São Paulo. 
MÉTODOS: Analisamos sequencialmente a amplificação dos primers APO-B, D1S80, DxS52, FVW, 33,6, YNZ-22, H-ras pelo VNTR (variable number of 
tandem repeats) em 17 pares e FISH (fluorescent in situ hybridization) pela sonda XY e do primer SRY em 13 pares de não relacionados a sexo.
RESULTADO: A informatividade dos primers pelo VNTR foi de 60% para APO-B; 75% D1S80; 36% DxS52; 14% FVW; 40% YNZ-22 e 16% H-ras. O primer SRY 
foi informativo em receptores femininos com doadores masculinos. O método XY-FISH foi informativo em 100% dos pares de não relacionado a sexo.
CONCLUSÃO: Estes métodos foram sensíveis e informativos. No VNTR, a associação do APO-B com D1S80 mostrou 88% de informatividade. O FISH, 
método quantitativo, foi mais sensível, porém com desvantagem de ser usado somente nos pares não relacionados a sexo. 
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INTRODUCTION
Non-myeloablative hematopoietic stem cell transplantation (NMA-
HSCT) is indicated for patients who cannot tolerate conventional ab-
lative regimens because of older age or the presence of comorbidities. 
Non-myeloablative regimens do not completely eliminate the cells from 
the host. Initially, both donor and recipient cells are present, a con-
dition known as mixed chimerism. This state of mixed chimerism is 
subsequently converted into complete chimerism through infusions of 
the donor’s lymphocytes or manipulation of immunosuppression dur-
ing the post-transplant period. The persistence of mixed chimerism, re-
gardless of whether ablative or non-myeloablative conditioning is per-
formed, results in relapses.1-3
Host involvement through graft-versus-host disease generally oc-
curs concurrently with complete chimerism. Successful clinical manip-
ulation of graft-versus-host disease is desirable because it is usually asso-
ciated with eradication of the underlying disease through the graft-ver-
sus-tumor effect. Full chimera means complete chimerism of immune 
and hematopoietic cells, consisting of 100% donor cells, and is the main 
factor for achieving definitive cure.
After transplantation, chimerism analysis provides important clin-
ical information, such as in relation to total or partial reconstitution 
of the immune system and hematopoiesis in grafted cells. Evaluations 
on the polymerase chain reaction (PCR), markers for polymorphism 
loci of variable number tandem repeats (VNTR) and short tandem re-
peats (STR) inform the degree of chimerism in sex-matched and sex-
unmatched transplants. These techniques allow assessment of both 
pairs, or differentiation between donor and host deoxyribonucleic acid 
(DNA). The fundamental principle of the VNTR and STR techniques 
is that they distinguish DNA patterns between the donor and host by 
means of a panel of specific primers prior to transplantation. Once such 
a panel has been established, post-transplant monitoring of chimerism 
becomes applicable. The intensity of chimerism that is found depends 
on identifying and measuring genetic markers that vary between the do-
nor and host.3,4 
The conventional cytogenetic analysis that is classically used to as-
sess chimerism following sex-unmatched transplantation is inappropri-
ate because only small numbers of cells undergoing mitosis are available 
after transplantation. This difficulty is explained by the hypocellularity 
of the bone marrow, which can persist for months after the infusion, as 
well as by difficulties in inducing mitosis using the usual mitogens.1,5,6
Mixed chimerism is defined as the presence of donor cells in pro-
portions between 2.5 and 97%, within the cellular context of host he-
matopoiesis. XY fluorescent in situ hybridization (FISH) is used on sex-
unmatched pairs as a simple quantitative method for investigating this, 
and is applicable even when there are low numbers of cells in marrow 
samples.7 The XY probe allows two different colors to be viewed.8 Its 
resolution is high, but it can only be applied in cases of sex-unmatched 
transplants.6 The SRY marker can also be used to quantify the presence 
of the Y chromosome in sex-unmatched pairs.9-11 
NMA-HSCT can be performed with the patient either in the ward 
or in the outpatient clinic.12-14 The classical indications for non-my-
eloablative regimens are indolent disease such as chronic myeloid leuke-
mia, low-grade non-Hodgkin’s lymphomas, chronic lymphocytic leuke-
mia and mantle cell lymphoma.14-19 These diseases are intensely sensitive 
to the graft-versus-host effect. The diseases that present intermediate 
sensitivity to this immunological effect are acute myeloid leukemia, in-
termediate and high-grade non-Hodgkin’s lymphomas, multiple myelo-
ma and Hodgkin’s lymphoma.12,14-19
OBJECTIVE
The aim of this study was to evaluate the prevalence of chimerism 
in 21 patients with onco-hematological diseases who underwent NMA-
HSCT and the resolution of different techniques.
MATERIALS AND METHODS
Patient sample
This was a case series comprising 21 patients (14 males and seven fe-
males), with a mean age of 47 years and an average of two years of disease 
evolution prior to the transplantation. Three of the patients had under-
gone autologous stem cell transplantation previously. Two of the patients 
underwent transplantation presenting with positive minimal residual dis-
ease, seven with progressive disease and two with refractory disease.
All of the patients were included consecutively in this study, with-
out selection, between February 2003 and January 2006. Twelve pa-
tients were from Hospital Santa Marcelina and nine from Hospital São 
Paulo. Two donor/recipient sex-unmatched patients were subsequently 
included for XY-FISH analyses in 2006. All of the patients underwent 
matched HLA (human leukocyte antigen)-identical NMA-HSCT. The 
non-myeloablative conditioning regimen protocols included 14 of the 
21 patients, who used fludarabine in their regimens.13,15-19 Six multi-
ple myeloma patients received melphalan doses lower than 140 mg/m² 
and one received 120 mg/m² plus 120 mg/m² of cyclophosphamide as 
their conditioning.15 The prophylaxis for graft-versus-host disease con-
sisted of cyclosporine-A plus methotrexate for all settings.17,18 The infec-
tious disease prophylaxis that was used followed the universally known 
protocols.15-19 This study was previously approved by the Research Eth-
ics Committees of both institutions (Protocol numbers 18/2005 and 
1162/03 for Hospital Santa Marcelina and Hospital São Paulo, respec-
tively) and an informed consent statement was signed by all patients 
and their donors.
Table 1 presents the characteristics of the patient sample: numbers 
of patients, clinical situation (underlying diseases and patients’ clinical 
situation before transplantation), recipient and donor genders, comor-
bidities, age at the time of transplantation and duration of illness until 
the transplantation was performed.
Chimerism prevalence evaluation
This was a cross-sectional prevalence study on chimerism. We used 
the VNTR technique on 17 pairs and FISH with XY probe on sex-un-
matched pairs. The chimera evaluations were done sequentially prior 
to transplantation in order to define the different primer pairs between 
the donor and recipient. DNA amplification was done on the patients 
on days 30, 60, 120, 180 and 360, and subsequently, much later af-
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ter transplantation (+1200 days), on two patients. The results from the 
VNTR technique were correlated with those from FISH.
We used the VNTR technique to analyze the DNA obtained from 
the total peripheral blood leukocytes of the donor and recipients. Mark-
ers were selected based on their characteristics, degree of resolution or 
presence of polymorphism in multiple alleles, with homogeneous dis-
tribution frequency in populations previously studied 3,6,18-31 and con-
sequently a high degree of heterozygosity (Table 2). The SRY mark-
er was chosen for examining transplantations from sex-unmatched do-
nors, in order to determine whether the Y chromosome was present or 
absent.10,11 XY-FISH was performed on total bone marrow cells in the 
first and final evaluation of chimerism after transplantation from sex-
unmatched donors.8
DNA from recipients and donors was extracted using the Perfect 
gDNA Blood Mini-isolation kit (Eppendorf, Germany).22 It was am-
plified using the polymerase chain reaction (PCR) technique, by means 
of a thermocycler (Perkin Elmer 9700), for eight pairs of specific prim-
ers for each sequence. The characteristics of the chromosomal locations, 
base pair sequences and sizes of the amplified fragments are shown in 
Table 3 and the amplification conditions are shown in Table 4.
XY-FISH
The XY-FISH method was carried out using fresh material. We col-
lected 3 to 5 ml of bone marrow samples into syringes containing so-
Table 1. Characteristics of patient sample: numbers of patients, underlying disease, age at the time of transplantation, recipient and donor genders, 
comorbidities and duration of illness until transplantation was performed
Patient Disease Age (years) Sex R/D Pre-HSCT status Comorbidities Evolution (months)
4 MM 28 M/F PD, MM-IIIA - 10
8 MM 56 M/F PD, post-AHSCT, MM-IIIA - 44
10 MM 53 M/F MM-IIIA CRF 18
12 MM 53 F/M MM-IIIA OB 12
17 MM 46 M/M PD, MM-IIIA - 8
18 MM 48 M/M 2nd PR, MM-IIIB - 5
09 MM 49 F/M PD, post- AHSCT, MM-IIIA - 69
15 MM 42 F/F PD, MM-IIIA DVT-LL 11
14 C-CML 39 F/F C-CML SKS, CRRF 36
3 MDS 55 M/F 7q-(T-RAEB), MDS CA-HCV 6
6 AML-M3 33 F/M MRD, AML-M3 CCF* 18
7 AML-M2 20 M/F Recurrence post-AHSCT, AML-M2 CCF* 8
13 MDS 63 M/F 5q-RAEB, MDS DM, HT 30
16 AML 59 M/M 2nd MDS, 1st CR, AML CCC, HT 13
21 C-CML 53 M/M C-CML CCF 24
1 CLL 47 M/F Binet C, MRD, CLL - 16
2 FL 44 M/F Relapsed IVB, FL-GII, - 36
5 NHL 38 M/F RD rich in T cell, IVB, DLBCL AC, HPV 33
11 NHL 58 F/M DP, post-AHSCT, MM-IIIB, GII, FL COPD 28
19 CLL, RS 53 M/M DP, CLL, RS
CA-HBV, 
DM, HT, OB
96
20 NHL 48 F/F MF HT 10
IVB = stage IVB (Ann Arbor), bone marrow or liver disease infiltration; AML-M3 = promyelocytic acute myeloid leukemia; AML-M2 = acute myeloid leukemia with differentiation (FAB-M2); RAEB = refractory anemia with excess of 
blasts; MM-IIIA or B = multiple myeloma with Durie & Salmon stage III A (without renal failure) or B (with renal failure); FL-GII = follicular lymphoma grade II; CRF = chronic renal failure; DVT-LL = deep vein thrombosis of lower limbs; 
Sex R/D = sex of recipient/donor; M = Male; F = Female; PD = progressive disease; RD = refractory disease; AHSCT = autologous hematopoietic stem cell transplantation; OB = obesity; MRD = minimal residual disease; CR = com-
plete remission; PR = partial remission; CCF = congestive cardiac failure, CCF* = congestive cardiac failure secondary to use of anthracyclines; CA-HBV = chronic active hepatitis B virus, CA-HCV = chronic active hepatitis C virus; 
HT = hypertension; CCC = chronic calculous cholecystitis; DM = diabetes mellitus; SKS = severe kyphoscoliosis; CRRF = chronic restrictive respiratory failure; COPD = chronic obstructive pulmonary disease; FL = follicular lymphoma; 
DLBCL = diffuse large B cell lymphoma; MF = mycosis fungoides; MDS = myelodysplastic syndrome; AC = alcoholic cirrhosis; RS = Richter syndrome; HPV = herpes papillomavirus, C-CML = chronic phase of chronic myelogenous 
leukemia; NHL = non-Hodgkin’s lymphoma; CLL = chronic lymphocytic leukemia.
Table 2. Markers according to amplification and resolution
Marker DNA amplification Resolution
APO-B 16/17 (94%) 10/16 (62.5%)
DS180 15/17 (88%) 10/15 (75%)
DxS52 11/17 (64%) 4/11 (36%)
FVW 14/17 (82%) 2/14 (14%)
33.6 10/17 (58%) 4/10 (40%)
YNZ-22 15/17 (88%) 7/15 (47.6%)
H-ras 6/17 (35%) 1/6 (16.6%)
All markers 17/17 (100%) 16/17 (94%)
dium heparin. We then removed the leukocyte layer, which had been 
fixed in Carnoy’s solution, and subsequently prepared microscope slides. 
These were denatured and hybridized in accordance with the protocol 
from the probe manufacturer (Vysis, Inc, United States). The slides were 
evaluated under an epifluorescence microscope with diamidinophe-
nylindole (DAPI), fluorescein isothiocyanate (FITC) and rhodamine 
filters. The images were captured using the MacProbe 4.4 computer 
software (PowerGene System, Applied Imaging Corporation, United 
States) and scanned. The red (rhodamine) signal corresponded to the re-
gion of the Y chromosome and green (fluorescein) signal to the region of 
the X chromosome. Cells with two green signals were interpreted as fe-
male (XX) and cells with one green and one red signal, as male (XY).8
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Table 3. Primer sequences used in variable number of tandem repeats (VNTR) technique
Primer Chromosome location Primer sequence Product (base pairs) Reference
APO-B 2p23 – p24
5’ ATG GAA ACG GAG AAA TTA TG 3’
500 to 900 21
5’ CCT TCT CAC TTG GCA AAT AC 3’
D1S80 1p35 – p36
5’ GAA ACT GGC CTC AAC ACT GCC CGC C 3’
250 to 650 25
5’ GTC TTC TTG GAG GCA CGT GCC CCT T 3’
DxS52 Xq26 – q28
5’ CGA AGA GTG AAG TGC ACA GG 3’
650 to 3000 23
5’ CAC AGT CTT TAT TCT TCA GCG 3’
FVW 12p13-3
5’ AGC TAT ATA TCT ATT TAT CAT 3’
300 to 700 26
5’ ACA TAC ATA CAT AGA TAT AGG 3’
33.6 1q
5’ TGT GAG TAG AGG AGA CCT CAC 3’
5’AAA GAC CAC AGA GTG AGG AGC 3’
500 to 1000 27
H-ras 11p15.5
5’ TTG GGG GAG AGC TAG CAG GG 3’
5’ CCT CCT GCA CAG GGT CAC CT 3’
1000 to 2600 27
YNZ-22 17p13.3
5’ GGT CGA AGA GTG AAG TGC ACA G 3’
5’ GCC CCA TGT ATC TTG TGC AGT G 3’
200 to 2000 27
SRY Y
5’ TCG CGA TTA AGT CAA ATT CGC 3’
5’ CCC CCT AGT ACC CTG ACA ATG TAT T 3’
136 24
RESULTS
The VNTR technique was evaluated for 17 of the 21 patients. Four 
patients (# 1, 2, 9 and 13) were only analyzed using the FISH method 
with XY probe. Among these four, cases 1 and 2 were analyzed 1200 
days after the transplant. Case 9 was analyzed on days 60 and 360, and 
case 13 only on day 360. Cases 1 and 2 did not form part of the first 
period of this study and, in cases 9 and 13, no donor/recipient DNA 
analysis was obtained prior to transplantation, but in all these cases, 
the probe evaluated using XY-FISH documented complete chimerism. 
Even though these cases were not evaluated using the VNTR technique 
prior to transplantation, the complete chimerism found using the XY 
probe was confirmed by the SRY marker. The other sequence primers 
were found to be the following after transplantation: APO-B (cases 1, 
2, 9 and 13), D1S80 (1, 2, 9 and 13), FWF (1 and 2), 33.6 (1 and 2), 
YNZ-22 (1, 2, 9 and 13), DxS52 (9) and H-ras (9).
A panel of markers consisting of APO-B, D1S80, YNZ-22, 33.6, 
DxS52, FVW, H-ras and SRY was used for the other 17 patients and the 
results obtained are described below. 
Case 3 was an extension of DNA fragments that were identical for 
recipient and donor, to the APO-B, D1S80, DxS52, FWF and 33.6 
markers. The donor and recipient bands for the YNZ-22 and H-ras 
markers failed to be obtained. A review using XY-FISH on day 30, 
showed mixed chimerism with XX cells accounting for 85%. The donor 
for this particular patient was his mother. 
Evaluation of the product from APO-B showed results in 16 cases 
(94%), with information only on 10/16 patients (62.5%). Cases 5, 6, 
8, 10, 12, 14, 16, 17 and 22 showed different bands for these markers. 
It should be noted that patients 5, 16 and 21 only showed the APO-B 
marker through the VNTR technique (Table 2).
With the D1S80 marker, amplification occurred in relation to 15 
patients (88%); but information was found relating to 10/15 (75%). 
For 5/17 (29%), informative bands were present using the APO-B and 
D1S80 primers (cases 6, 8, 12, 14 and 17). On the other hand, regarding 
the panel composed only of the D1S80 and APO-B primers, resolution of 
chimerism occurred in relation to 15/17 pairs (88%). Only cases 3 and 20 
showed no information relating to either of these two markers.
With the YNZ-22 marker, amplification was observed in relation to 
15/17 (88%), but information was seen relating to 7/15 (47.6%). Pa-
tients 4, 6, 8, 10, 11, 12 and 18 showed information with this marker. 
Case 18 was also evaluated using the STR primer (not shown), present-
ing complete chimerism through both methods at the same time.
Using the DxS52 marker, amplification showed a DNA product 
for 11/17 patients (64%), but information relating to this marker 
Marker Denaturing Girdling/extension (temperature, time, number of cycles) Reference
APO-B 94 °C, 1 min 58 °C (6 min) x 26 28
D1S80 94 °C, 1 min 65 °C (1 min); 70 °C (5 min) x 28 29
DxS52 94 °C, 20 sec 55 °C (30 sec); 74 °C (20 sec); final 74 °C (5 min) x 24 23
FVW 94 °C, 20 sec 48 °C (20 sec); 72 °C (20 sec) x 30 26
33.6 95 °C, 1 min 60 °C (45 sec); 72 °C (1 min); 72 °C (10 min) x 35 22
H-ras 94 °C, 5 min
95 °C (1 min); 64°C (2 min); 72 °C (6 min)
64 °C (2 min); 72 °C (10 min)
x 20
x 01
30
YNZ-22 95 °C, 1 min 60 °C (45 sec); 72 °C (1 min); 72 °C (10 min) x 30 22
SRY 95 °C, 10 min
95 °C (15 sec); 60 °C (1 min); 72 °C (1 min); 
final  72 °C (7 min)
x 50
24
Table 4. Conditions for primer amplification
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was seen in only four pairs (36%): patients 4, 7, 11 and 19. With the 
FVW marker, amplification was seen in relation to 14/17 (82%), but 
information from this marker was documented in only two patients 
(14%): cases 4 and 7. Using the 33.6 marker, amplification was seen 
in relation to 10/17 (58%) and there was pretransplantation infor-
mation for 4/10 (40%). Cases 7, 10, 12 and 20 presented resolution 
with this marker. It should be noted that case 20 only had the 33.6 
primer as a marker.
Case 7 showed mixed chimerism documented using XY-FISH, with 
only 34% of the cells coming from the donor. This finding was con-
firmed using the D1S80, DxS52 and 33.6 primers. With the FVW 
marker, there was no grafting, and this was a different result. The inter-
pretation was that this was mixed chimerism due to the other primers. 
On day 90, this patient presented molecular relapse, which was con-
firmed by information from all of the primers investigated. It should 
be noted that no acute or chronic graft-versus-host disease involvement 
was seen in this patient. Hematological relapse occurred 120 days after 
transplantation (Figures 1).
XY-FISH analysis on day 30 showed that 99% of the cells were 
from the donor in cases 4 and 10 and 97% in cases 5 and 12. Analysis 
using the VNTR technique concomitantly showed that case 4 presented 
complete chimerism with D1S80, DxS52, FVW and YNZ-22; case 5 
with APO-B; case 10 with APO-B, 33.6 and YNZ-22; and case 12 with 
APO-B, D1S80, 33.6, YNZ-22 and SRY.
Evaluation using the SRY primer on female recipients with male 
donors enabled analysis on four cases and documented complete chi-
merism in three of them (cases 6, 11 and 12). On the other hand, in 
case 9, this marker and other markers were not evaluated on day 30 
but, as mentioned earlier, XY-FISH documented complete chimerism 
on day 60.
With regard to male recipients with female donors, the SRY mark-
er did not give information for analyzing chimerism, because all these 
recipients had the Y chromosome, regardless of the time at which they 
were examined and regardless of the outcome of complete chimerism 
diagnosed using XY-FISH.
Thirteen patients were analyzed using XY-FISH. Of these, four were 
female recipients (# 6, 9, 11 and 12) and seven were male (# 1, 2, 3, 
5, 6, 7, 8, 10 and 13). This was the most sensitive method, and it al-
lowed evaluation of chimerism in patients 1, 3, 2, 9 and 13, who had 
not been investigated regarding DNA prior to transplantation. From 
the SRY marker, it was seen that the female recipients kept the male Y 
chromosome, thus leading to an interpretation of complete chimerism, 
in combination with the XY-FISH probe results.
DISCUSSION
The resolution found using APO-B was 10/16 (62.5%). It was 
noteworthy in relation to this set of primers that cases 5, 16 and 
21 only had the APO-B primer as a marker for chimerism. Stup-
pia et al.25 documented resolution in 25% of Caucasian pairs using 
D1S80. According to Martinelli et al.,20 D1S80 was the main marker 
in their cases with resolution of 6/6 cases. Muniz et al.31 found 66% 
resolution. In our series, amplification occurred in 88% of the cas-
es (15 pairs) and resolution in 10/15 (75%). We emphasize the fact 
that 5/17 patients (29%) presented resolution using the APO-B and 
D1S80 primers, but when we summed the separate results, combin-
ing them for both primers, there was information on 15 of the 17 
pairs (88%). Thus, combination of these two primers had great ap-
plicability in our series.
DxS52 was investigated by Stuppia et al.,25 and they obtained reso-
lution in 4/6 cases (66.6%). There was successful amplification of the 
DNA fragment from 11/17 pairs (64%), at different times after trans-
plantation, but the degree of resolution among our patients was 4/11 
(36%), i.e. lower than that described by Stuppia et al.25
FVW was analyzed in relation to 35 pairs by Muniz et al.31 and 
resolution was detected in 15 (43%). In our series, despite the suc-
cess of amplification in relation to 14/17 patients (82%), there was 
resolution in only 2/14 (14%). This was also seen with H-ras, which 
gave information only in the case of one patient (case 17), and there 
was difficulty in amplification in 11/17 cases (65%). Our data for 
H-ras therefore differ from those of Hassan et al.,30 who observed 
36% resolution in cases of aplastic anemia, and were closer to the 
data of van Leeuwen et al.,32 who found resolution relating to only 
11% of 37 pairs.
We succeeded in amplifying YNZ-22 in 15/17 pairs (88.8%), and 
the resolution was 7/15 (47%). Hassan et al.30 found that the resolution 
of this primer was 50%, among individuals with aplastic anemia. The 
33.6 primer gave information in relation to 40% (4/10), and this per-
centage was lower that described by Hassan et al.30
The resolution found for this panel of primers was as follows: 
D1S80, 10/15 patients (75%); APO-B, 10/16 (62.5%); YNZ-22, 
7/15 (47%); 33.6, 4/10 (40%); DxS52, 4/11 (36%); FVW, 2/14 
Figure 1. Evaluation using 2% agarose gel electrophoresis marker D1S80 
following polymerase chain reaction (PCR) amplification (variable number 
of tandem repeats, VNTR technique) in case 7. (1) donor product;  
(2) patient product before transplantation; (3) and (4) donor and 
patient products after transplantation; (5) and (6) patient products after 
transplantation and after molecular relapse; (7) 100-base pair marker.
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(14%); and H-ras, 1/6 (16.6%). YNZ-22 and FVW were easily am-
plified; YNZ-22 showed intermediate resolution, but FVW showed 
the lowest heterozygosity. We stress the importance of using larger 
numbers of primers in such panels, in order to achieve relevant results. 
Case 3 provides an example: this showed mixed chimerism through 
XY-FISH but the VNTR technique failed to show chimerism, since 
successful amplification of the APO-B, D1S80, DxS52, FVW and 
33.6 primers showed homozygous bands. The importance of this pan-
el was shown by the fact that patients 5, 15, 16, 20 and 21 presented 
only one primer marker. APO-B was the marker in cases 5, 16 and 21; 
D1S80 in case 15; and 33.6 in case 20.
The informativeness of each individual locus in VNTR/STR var-
ies between different individuals and, therefore, the polymerase chain 
reaction products are of different lengths depending on the tandem re-
peats. Currently, DNA-based technologies are the methods of choice 
for chimerism analysis, mainly because of their sensitivity for detecting 
the presence of minor proportions of recipient clone cells after trans-
plantation. Ariffin et al.4 evaluated individuals of Malay and Chinese 
ethnicity using two commercially-available forensic kits that are also 
widely used for multiplex and monoplex STR. In their cases, amplifi-
cation and genotyping using this method revealed six out of 15 STR 
loci, which enabled resolution of 31 out of 33 cases (94%): TH01 
(73%), VWA (73%), FIA0I (52%), CSFIPO (61%), FESFPS (39%) 
and TPOX (45%).4 A combination of STR and VNTR markers test-
ed by Talwar et al.3 in relation to hematopoietic stem cell transplanta-
tion cases and normal subjects in northern India demonstrated that 
the APOB’HVR, FES, VWA, D3S1358 and D16S310 loci were the 
most polymorphic of the 15 loci analyzed, with mean heterozygosity 
of 0.756 ± 0.17. A panel composed of these seven primers was able to 
differentiate 98.7% of the donor-recipient pairs out of the 77 settings 
tested. We emphasize that APO-B and D1S80 made resolution pos-
sible for 88% of our patients, but a larger population of both normal 
individuals and hematopoietic stem cell transplantation cases needs to 
be evaluated in order to reach a final conclusion.
The FISH XY probe was used in the cases of 13 patients, with the 
first sample on day 30 and the second concomitantly with the last col-
lection for the VNTR technique. For four patients (1, 2, 9 and 13), no 
DNA analysis was performed prior to transplantation and although the 
VNTR technique showed homozygous bands, the final chimerism anal-
ysis was certified by means of XY-FISH.
The sensitivity of the XY-FISH method ranges from 0.7 to 5%.6 
Two out of four patients had FISH values of 99 and 99.5% on day 30 
(cases 4 and 10, respectively). In case 4, the D1S80, DxS52, FVW and 
YNZ-22 primers showed qualitative results with complete chimerism 
and in case 10, the APO-B, 33.6 and YNZ-22 primers presented equal 
results. Both of these patients displayed complete chimerism in subse-
quent evaluations, on days 60, 90, 120, 180 and 360 in case 10 and on 
all these occasions plus day 1200 in case 4. For patients 5 and 12, XY-
FISH showed that the proportions of donor cells were 97 and 97.5%, 
respectively, in the evaluation on day 30. Patient 5 only had the APO-B 
primer as a marker, while patient 12 had APO-B, D1S80, 33.6 and 
YNZ-22. On day 30, both of these patients presented complete chime-
rism. Further evaluations, which continued until day 180 for patient 
12 and until day 120 for patient 5, documented complete chimerism 
according to the VNTR technique. For these two patients, XY-FISH 
at the last evaluation was also compatible with complete chimerism. 
In all the other evaluations using the XY probe, totaling 19 simultane-
ous analyses, the degree of chimerism was coincident with the results 
for primer markers using the VNTR technique, which included the in-
terpretation of day 30 for cases 4 and 10. From these results, it can be 
concluded that the XY probe, as assessed using FISH, which is feasi-
ble only for sex-unmatched pairs, is a more sensitive method than the 
VNTR technique, especially for early assessments following transplan-
tation. Thus, for the NMA-HSCT technique, XY-FISH is important 
because of its outstanding capability for determining whether or not to 
perform donor lymphocyte infusion (DLI) in order to obtaining com-
plete chimerism. 
It should be noted that the analysis of hematopoietic chimerism 
using the XY probe does not depend on data collection prior to trans-
plantation, as does the VNTR interpretation. The interpretation of XY 
probe data is quantitative and more decisive than is the qualitative or 
semiquantitative assessment of VNTR data. Today, single nucleotide 
polymorphism, STR and Y-chromosome-specific sequences analyzed by 
polymerase chain reactions (PCR) are the best methods for carrying out 
a quantitative evaluation of chimerism. Koldehoff et al.11 reported that 
single nucleotide polymorphism using 10 different gene loci discrimi-
nated patient cells from donor cells in 125 out of 135 pairs (93%), while 
STR performed with 11 different genes resulted in accurate donor-host 
discrimination in all pairs. The results from the two methods were 74% 
concordant, but the single nucleotide technique detected mixed chi-
mera earlier than STR did, thus enabling earlier interventions. Using 
a multivariate Cox model, this method was the only significant factor 
predicting relapse.
Studies on chimerism are of fundamental importance for the final 
diagnosis to explain why rejection occurs and for clarifying the etiol-
ogy of hypoplasia following transplantation and any recurrences of 
the underlying disease. In this study, we evaluated the presence of SRY 
using normal controls consisting of male and female individuals who 
had not undergone transplantation. We observed four cases of female 
recipients with male donors, showing complete chimerism according 
to XY-FISH. This result was identical to that obtained through analy-
sis of SRY in the DNA of blood cells. Meanwhile, seven male patients 
with female donors presented complete chimerism according to XY-
FISH, but they were positive for SRY, from evaluation of the DNA of 
their blood cells. The control that we used in each amplification reac-
tion was DNA from normal males and females, but even if different 
samples were evaluated at different times, the results from these pa-
tients were always convergent using the SRY technique and divergent 
using the FISH technique. Koldehoff et al.11 analyzed the status of 
male recipients with female donors in 580 samples from 134 patients, 
using a quantitative real-time polymerase chain reaction (RT-PCR) on 
Y-chromosome specific sequences. They compared the results with in-
terphasic XY-FISH and demonstrated the presence of mixed chime-
rism without signs of relapse in 35% of the samples. Otherwise, the 
quantities of Y-DNA detected were low, compared with the amounts 
detected in 104 samples from relapsed leukemia patients at the time of 
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analysis. Importantly, the amount of host DNA increased sequentially 
in relapsed patients, thereby proving that mixed chimerism becomes 
enhanced and possibly predicts relapse (which occurred after approxi-
mately 143 days in this study). The results were concordant with XY-
FISH findings in 73% of the patients. However, XY-FISH detected 
relapses only in 12 settings and Y-chromosome polymerase chain reac-
tions detected 36, by means of sequential evaluation of mixed chime-
rism. Based on our results, we ruled out the use of quantitative meth-
ods for evaluating chimerism in male recipients using the SRY primer, 
and the results must be interpreted with caution.
CONCLUSION
1. The VNTR technique enabled evaluation of chimerism in 17 out 
of 21 patients, and the primers used presented the following resolu-
tion: APO-B (62.5%), D1S80 (75%), DxS52 (36%), FWF (14%), 
33.6 (40%), YNZ-22 (47%) and H-ras (16.6%).
2. The XY-FISH technique, which was used for 13 cases in which the 
donor and recipient were of different genders, showed quantitative 
resolution of chimerism in 100% of cases.
3. In two patients, mixed chimerism was identified. In these pairs, 
there were discrepancies in the assessment of chimerism on day 
30 between the XY-FISH and VNTR techniques. XY-FISH 
identified 95% and 97% mixed chimerism and the VNTR tech-
nique showed complete chimerism at this stage of the procedure. 
In other patients and at other times, the two methods were coin-
cident.
4. The SRY primer proved to be capable of resolution only in cases 
of female recipients when their results were coincident with those 
from XY-FISH.
5. When the APO-B and D1S80 primers were considered in the pan-
el, this enabled resolution of chimerism in 15 out of 17 patients 
(88%).
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